Business Description
CEL-SCI Corp
NAICS : 541713
SIC : 2836
ISIN : US1508376076
Description
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 1.04 | |||||
| Debt-to-EBITDA | -0.5 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 5.6 | |||||
| 3-Year EPS without NRI Growth Rate | 2.6 | |||||
| 3-Year FCF Growth Rate | -2.2 | |||||
| 3-Year Book Growth Rate | -18.2 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.67 | |||||
| 9-Day RSI | 26.9 | |||||
| 14-Day RSI | 30.36 | |||||
| 6-1 Month Momentum % | 21.19 | |||||
| 12-1 Month Momentum % | -27.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | |||||
| Quick Ratio | 0.78 | |||||
| Cash Ratio | 0.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7 | |||||
| Shareholder Yield % | -4.14 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -177.65 | |||||
| ROA % | -89.07 | |||||
| ROIC % | -116.52 | |||||
| ROC (Joel Greenblatt) % | -137.96 | |||||
| ROCE % | -102.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.81 | |||||
| Price-to-Tangible-Book | 5.9 | |||||
| EV-to-EBIT | -2.94 | |||||
| EV-to-EBITDA | -3.38 | |||||
| EV-to-FCF | -3.8 | |||||
| Earnings Yield (Greenblatt) % | -34.01 | |||||
| FCF Yield % | -29.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CVM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CEL-SCI Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.68 | ||
| Beta | 0.81 | ||
| Volatility % | 76.37 | ||
| 14-Day RSI | 30.36 | ||
| 14-Day ATR ($) | 0.127083 | ||
| 20-Day SMA ($) | 1.688 | ||
| 12-1 Month Momentum % | -27.38 | ||
| 52-Week Range ($) | 1.04 - 3.23 | ||
| Shares Outstanding (Mil) | 53.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CEL-SCI Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CEL-SCI Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CEL-SCI Corp Frequently Asked Questions
What is CEL-SCI Corp(CVM)'s stock price today?
The current price of CVM is $1.47. The 52 week high of CVM is $3.23 and 52 week low is $1.04.
When is next earnings date of CEL-SCI Corp(CVM)?
The next earnings date of CEL-SCI Corp(CVM) is 2024-05-13 Est..
Does CEL-SCI Corp(CVM) pay dividends? If so, how much?
CEL-SCI Corp(CVM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers